VITAMIN D AND POLYNUCLEOTIDES IN THE TREATMENT OF OSTEOARTHRITIS

DOI: https://doi.org/10.29296/25877305-2023-09-07
Issue: 
9
Year: 
2023

M. Kashpanov(1); Professor I. Novikova(2), MD; A. Pronkina(3)
1-Murmansk City Polyclinic Two
2-Northern State Medical University, Arkhangelsk
3-Penza State University

Osteoarthritis occupies a leading position among the causes of disability in patients with rheumatic diseases. The wide prevalence of pathology and the high risk of disability predetermine the need to prevent its development, improve the effectiveness of treatment and conduct rehabilitation measures. The article presents a clinical case on the use of vitamin D and its active metabolites, polynucleotide preparations in the treatment of osteoarthritis. Long-term intake of high doses of vitamin D leads to a decrease in the intensity of pain and functional deficit in patients with osteoarthritis. Vitamin D and its active metabolites compensate for the deficiency of cholecalciferol and thereby reduce the intensity of synovial inflammation in osteoarthritis, at maximum dosages demonstrate a chondroprotective effect by inhibiting apoptosis of chondrocytes, and in the early stages prevent non-adaptive remodeling of the subchondral bone. The results of fundamental and randomized clinical trials allow us to conclude that it is advisable to include vitamin D in the complex therapy of osteoarthritis. It is important to include vitamin D in complex therapy in the early stages of the disease. In addition, there is information in the literature about the use of polynucleotide preparations in the treatment of osteoarthritis. Against the background of treatment with polynucleotide preparations, it is possible to delay the time to arthroplasty, and the need to take non-steroidal anti-inflammatory drugs and opioids decreases.
Keywords: 
clinical case
osteoarthritis
polynucleotide
vitamin D
Osteo-Vit D3.

References: 
  1. Балабанова Р.М., Дубинина Т.В., Демина А.Б. и др. Заболеваемость болезнями костно-мышечной системы в Российской Федерации за 2015–2016 гг. Научно-практическая ревматология. 2018; 56 (1): 15–21 [Balabanova R.M., Dubinina T.V., Demina A.V. et al. The incidence of musculoskeletal diseases in the Russian Federation over 2015–2016. Rheumatology Science and Practice. 2018; 56 (1): 15–21 (in Russ.)]. DOI: 10.14412/1995-4484-2018-15-21
  2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, аnd years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392 (10159): 1789–858. DOI: 10.1016/S0140-6736(18)32279-7
  3. Мартынов А.И., Наумов А.В., Верткин А.Л. и др. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике: мнение экспертов, основанное на доказательной медицине. Лечащий врач. 2015; 4: 39–46 [Martynov A.I., Naumov A.V., Vertkin A.L. et al. Observation of the patients with osteoarthritis with comorbidity in general medical practice: expert opinions based on evidentiary medicine. Lechaschi Vrach. 2015; 4: 39–46 (in Russ.)].
  4. Veronese N., Cereda E., Maggi S. et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016; 46 (2): 160–7. DOI: 10.1016/j.semarthrit.2016.04.002
  5. Kovari E., Kaposi A., Bekes G. et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2020; 50 (2): 183–91. DOI: 10.1016/j.semarthrit.2019.09.001
  6. Мурманская область в цифрах. Федеральная служба государственной статистики, Территориальный орган Федеральной службы государственной статистики по Мурманской области. Мурманск, 2021; 127 с. [Murmansk region in figures. Federal State Statistics Service, Territorial body of the Federal State Statistics Service for the Murmansk region. Murmansk, 2021; 127 p. (in Russ.)].
  7. Купцова Т.А., Струков В.И., Елистратов Д.Г. и др. Остео-Вит D3 в лечении детей с переломами костей на фоне низкой минеральной плотности. В сб.: Апитерапия сегодня: мат-лы XVIII Всеросс. науч. конф. 2016; с. 27–8 [Kupczova T.A., Strukov V.I., Elistratov D.G. et al. Osteo-Vit D3 in the treatment of children with bone fractures on the background of low mineral density. In the collection: Apitherapy today: proceedings of the XVIII All-Russian Scientific Conference. 2016; рр. 27–8 (in Russ.)].
  8. Виноградова О.П., Сергеева-Кондраченко М.Ю., Панина Е.С. и др. Иммунотерапия остеоартроза на фоне остеопороза. Терапевт. 2023; 1: 6–15 [Vinogradova O.P., Sergeeva-Kondrachenko M.Yu., Panina E.S. et al. Immunotherapy of osteoarthritis against the background of osteoporosis. Therapist. 2023; 1: 6–15 (inRuss.)]. DOI: 10.33920/MED-12-2301-01
  9. Пешехонова Л.К., Пешехонов Д.В., Красюков П.А. Клиническая эффективность применения препаратов Остеомед, Остеомед Форте, Остео-Вит D3 у больных вторичным остеопорозом при ревматоидном артрите. Врач. 2020; 31 (4): 68–74 [Peshekhonova L., Peshekhonov D., Krasyukov P. The clinical efficiency of using Osteomed, Osteomed Forte, and Osteo-Vit D3 in patients with secondary osteoporosis in rheumatoid arthritis. Vrach. 2020; 31 (4): 68–74 (in Russ.)]. DOI: 10.29296/25877305-2020-04-12
  10. Поликарпочкин А., Левшин И., Вовк Е. и др. Оценка применения эффективности гипербарической оксигенации и препарата «Остео-Вит D3» при лечении гонартрозов. Гипербарическая физиология и медицина. 2018; 1: 13–24 [Polikarpochkin A., Levshin I., Vovk E. et al. Evaluation of the effectiveness of hyperbaric oxygenation and preparation «Osteo-Vit D3» in the treatment of gonarthrosis. Giperbaricheskaya fiziologiya i meditsina. 2018; 1: 13–24 (in Russ.)].
  11. Струков В.И., Алексеева Н.Ю., Петрова Е.В. и др. Остеобиотик «Остео-Вит D3» как средство лечения и профилактики болезней опорно-двигательного аппарата медикаментозного генеза. Пятиминутка. 2020; 2 (57): 28–33 [Strukov V.I., AlekseevaN.Yu., Petrova E.V. et al. Osteobiotic "Osteo-Vit D3" as a means of treatment and prevention of diseases of the musculoskeletal system of medicinal genesis. Pyatiminutka. 2020; 2 (57): 28–33 (in Russ.)].
  12. Струков В.И., Елистратов Д.Г., Еремина Н.В. и др. Костные полости при остеопорозе и их роль в диагностике и терапии: методические рекомендации. Прага: Vědecko vydavatelské centrum «Sociosféra-CZ», 2021; 52 с. [Strukov V.I., Elistratov D.G., Eremina N.V. et al. Bone cavities in osteoporosis and their role in diagnosis and therapy: guidelines. Prague: Scientific publishing centre "Sociosphere-CZ", 2021; 52 p. (in Russ.)].
  13. Павлова Т.В., Башук И.П. Клинико-морфологические особенности дегенеративных изменений костной ткани на фоне остеопороза в возрастном аспекте. Врач. 2019; 30 (6): 47–50 [Pavlova T., Bashuk I. Clinical and morphological features of degenerative changes in bone tissue with osteoporosis in age aspects. Vrach. 2019; 30 (6): 47–50 (in Russ.)]. DOI: 10.29296/25877305-2019-06-11
  14. Струков В.И. Мировое открытие в борьбе с переломами и остеопорозом! Поликлиника. 2012; 5: 126–7 [Strukov V.I. A world discovery in the fight against fractures and osteoporosis! Poliklinika. 2012; 5: 126–7 (in Russ.)].